Metoclopramida Labesfal

Quick links

Choose a section

Quick links to important sections

Advertisements

Metoclopramida Labesfal

Advertisements

Overview of Metoclopramida Labesfal

Property Description
Active ingredient Metoclopramide
Forms Tablet, Oral solution, Injectable solution
Pharmacological class Prokinetic Agent, Antiemetic Agent
Origin Synthetic (Substituted Benzamide Derivative)
Route of administration Oral, Intravenous (IV), Intramuscular (IM)

Metoclopramida Labesfal is a prescription-only medicinal product containing the single active substance Metoclopramide (INN), which is precisely defined as a synthetic substituted benzamide derivative. The product functions as a dual-action agent, primarily classified as a Prokinetic Agent and an Antiemetic Agent, making it instrumental in regulating the movement of the upper digestive system and suppressing feelings of nausea.


What Type of Medicine is Metoclopramida Labesfal?

Metoclopramide is a pharmacological compound primarily categorized by its effects on specific chemical messengers in the body, most notably by acting as a Dopamine D2 Receptor Antagonist. This molecular action is responsible for both of its high-level classifications. As a Prokinetic Agent, the substance enhances the natural, forward-moving contractions of the muscles in the stomach and small intestine, thereby speeding up the transit of contents, an effect clinically recognized for its efficacy in managing conditions characterized by sluggish gastric movement.

Its secondary, yet critical, role as an Antiemetic Agent stems from its ability to block the dopamine-mediated signals in the brain’s chemoreceptor trigger zone (CTZ), which prevents the initiation of the vomiting reflex. Metoclopramide-containing products are recognized for their gastroprokinetic and antiemetic properties, confirming the dual purpose of the substance.


Available Forms and General Purpose

The medication is supplied for patient use in multiple dosage forms, including traditional tablets for oral intake, an oral solution that allows for dosage adjustment, and an injectable solution for parenteral administration via the intravenous (IV) or intramuscular (IM) route of administration. The drug's overall purpose is to restore coordinated movement in the upper digestive system. By accelerating stomach emptying and simultaneously blocking the brain’s nausea signals, the substance generally helps to relieve feelings of persistent nausea, prevent vomiting, and alleviate symptoms associated with sluggish stomach emptying.

Regulatory References

  1. European Medicines Agency (EMA)
Advertisements

What side effects are possible with Metoclopramida Labesfal?

Possible side effects and safety information

The documented safety profile for Metoclopramide is strictly based on adverse reactions monitored and classified by official regulatory bodies, using standard frequency categories and System Organ Class (SOC) definitions.

Adverse Reaction Frequencies

Frequency Examples of Officially Listed Reactions
Very Common (ge 1/10) Drowsiness
Common (ge 1/100 to < 1/10) Depression, Restlessness (Akathisia), Extrapyramidal disorders, Diarrhoea, Asthenia
Uncommon (ge 1/1,000 to < 1/100) Bradycardia, Hypotension, Confusion, Hallucinations
Rare (ge 1/10,000 to < 1/1,000) Seizures, Galactorrhoea, Amenorrhoea
Not Known Neuroleptic Malignant Syndrome (NMS), Tardive Dyskinesia, Methemoglobinaemia, Anaphylactic shock

The safety framework is primarily organized around effects on the Nervous System and Gastrointestinal Disorders. Acute extrapyramidal symptoms are officially documented as more common at the start of treatment or following dose escalation. In contrast, the risk of Tardive Dyskinesia is associated with long-term exposure.

Serious Safety Concerns and Specific Populations

Official labeling documents specific serious adverse reactions, including Neuroleptic Malignant Syndrome (NMS) and Methemoglobinaemia. Safety concerns are noted for certain populations. For older adults, the risk of Tardive Dyskinesia is increased with prolonged use. Pediatric patients, especially newborns, have an increased susceptibility to extrapyramidal disorders and Methemoglobinaemia. The medicine is officially contraindicated in patients with a history of Gastrointestinal Hemorrhage, Mechanical Obstruction, Perforation, or a known Pheochromocytoma. Dose adjustments may be required for individuals with renal impairment.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of Metoclopramida Labesfal is a serious situation requiring immediate medical intervention, as defined by government regulatory authorities. Official labeling describes specific neurological and cardiovascular manifestations that may occur following excessive exposure.

Documented Overdose Manifestations

System Clinical Manifestations (as documented)
Neurological Somnolence, confusion, disorientation, and the presence of extrapyramidal symptoms (EES). Severe outcomes include convulsions (seizures).
Cardiovascular Bradycardia (slowed heart rate), Torsade de Pointes, and potentially life-threatening events such as cardio-respiratory arrest, especially noted after intravenous administration.

Required Emergency Actions

Regulatory guidance explicitly mandates that patients must seek immediate medical attention for any suspected overdose. Emergency services must be contacted immediately if critical signs are present, including collapse, a seizure, difficulty breathing, or inability to be awakened.

Management and Specific Considerations

Official documentation states that no specific antidote is known for Metoclopramide overdose; therefore, management is limited to symptomatic and supportive treatment. Supportive measures include the use of benzodiazepines for controlling severe extrapyramidal reactions. Overdose considerations include the heightened risk of Methemoglobinemia in infants and neonates and the increased susceptibility of pediatric patients to extrapyramidal symptoms. Continuous cardiovascular and neurological monitoring is required.

Advertisements

Therapeutic Uses of Metoclopramida Labesfal

The medication is commonly used to help manage symptoms related to heightened physiological activity, providing supportive relief across various therapeutic domains. Its primary uses generally fall into two core categories aimed at easing the overall symptom burden.

Targeting Acute Nausea and Preventing Vomiting

This domain applies to situations involving certain distressing symptoms, where the drug generally helps address symptom clusters that may become intense or disruptive. It is commonly used when short-term symptomatic assistance is needed to help manage the sickness that follows specific procedures, such as radiotherapy or post-operative recovery, and may assist with the severe nausea associated with acute migraine headaches. This supports patients during difficult episodes by helping to ease distress.

“The medication provides supportive relief that helps ease the overall symptom burden.”

The medicine is used for managing conditions that produce significant symptomatic burden, including delayed gastric emptying (often seen in adult patients with diabetes), symptomatic Gastroesophageal Reflux Disease (GERD) in individuals where initial therapeutic approaches are insufficient, and for management of sickness related to surgery or cancer therapy.

Easing Symptoms of Sluggish Stomach Emptying

The medicine is relevant in conditions characterized by periods of heightened symptoms, specifically delayed gastric emptying. It is used for managing symptoms that interfere with daily comfort, such as persistent fullness after meals, vomiting, and discomfort from acid backflow. This assists with maintaining functional stability and supports general well-being during symptomatic phases. The medication is relevant in clinical settings that involve acute or unstable symptom patterns.


Quick Fact: Relief for Nausea and Vomiting and Persistent Fullness

Advertisements

Eligibility and Restrictions for Use

Official Population Eligibility for Metoclopramida Labesfal

The eligibility profile for Metoclopramida Labesfal, containing the active substance metoclopramide, is strictly defined by regulatory authorities based on age, pre-existing conditions, and physiological status. The medicine is primarily indicated for use in adults, with highly restricted use in children and adolescents.

Contraindications and Prohibited Use

Metoclopramida Labesfal must not be used in the following populations, as mandated by regulatory labeling:

  • Infants under 1 year of age.
  • Patients with pheochromocytoma, Parkinson’s disease, or epilepsy/seizures.
  • Individuals with gastrointestinal haemorrhage, mechanical obstruction, or perforation, as stimulating gut motility poses a risk.
  • Patients with a history of methemoglobinemia with metoclopramide or tardive dyskinesia with metoclopramide or other similar medicines.

Conditional Use and Restrictions

The medicine requires special consideration or a mandated dose adjustment in specific populations:

Population Group Regulatory Condition
Children (1–18 years) Restricted to second-line therapy for specific, approved indications.
Older Adults Special care required; dose reduction should be considered based on overall function.
Severe Renal/Hepatic Impairment Dose reduction is mandatory (e.g., 50% to 75% reduction) due to impaired drug clearance.
Pregnancy/Lactation Avoided at the end of pregnancy; not recommended for use during breastfeeding.
Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Metoclopramide's interaction profile is documented in regulatory labeling and involves both effects on how other medicines work (pharmacodynamics) and how the body handles them (pharmacokinetics).

  • Contraindicated Combinations: Co-administration with levodopa or dopaminergic agonists is prohibited due to mutual pharmacological opposition that nullifies the effects of both medications.

  • Increased Risk of Side Effects: Combining metoclopramide with other antidopaminergic agents (such as some antipsychotics) increases the risk of extrapyramidal reactions. Similarly, co-administration with CNS depressants (including alcohol and narcotic analgesics) increases sedation and central nervous system effects.

  • Altered Drug Absorption: Metoclopramide can change the absorption rate of certain medicines due to its effect on gastrointestinal motility. This can lead to decreased systemic exposure of drugs like digoxin and increased exposure of drugs like cyclosporine, often requiring a dose adjustment of the co-administered medicine.

  • Metabolic Pathway Inhibition: Metoclopramide is metabolized by the CYP2D6 enzyme system. Co-administration with strong inhibitors of CYP2D6 can significantly increase the concentration of metoclopramide in the body, potentially requiring a reduced dose to prevent adverse effects. This consideration is particularly relevant for patients identified as CYP2D6 poor metabolizers. Use with Monoamine Oxidase Inhibitors (MAOIs) is restricted due to the risk of hypertensive crisis.

Advertisements

Mechanism of Action

Metoclopramida Labesfal (metoclopramide) works through a dual mechanism that precisely modulates specific neurotransmitter receptors in both the digestive system and the brain. The drug acts as a D2 receptor antagonist (blocker) and a 5- HT4 receptor agonist (activator), resulting in two distinct patterns of physiological modulation.

Enhanced Motility via Cholinergic Potentiation

The prokinetic action is primarily confined to the upper gastrointestinal tract. By activating Serotonin 5- HT4 receptors and simultaneously blocking peripheral Dopamine D2 receptors in the gut's nerve network, the drug increases the localized release and effect of Acetylcholine (ACh). This enhanced cholinergic signaling leads to increased force and coordination of smooth muscle contractions in the stomach and small intestine, which establishes a pattern of accelerated gastric transit and increased tone of the Lower Esophageal Sphincter (LES).

Central Suppression of the Emetic Reflex

The antiemetic mechanism targets the brain's Chemoreceptor Trigger Zone (CTZ), which lies outside the blood-brain barrier. Metoclopramide blocks both Dopamine D2 and Serotonin 5- HT3 receptors within this center. By blocking these key signaling pathways, the drug prevents chemical messengers from activating the CTZ and activating the central emetic pathway, resulting in the physiological effect of inhibition of the central emetic response.

Advertisements

Dosage and Administration Information

How to Use Metoclopramida Labesfal

Metoclopramida Labesfal (metoclopramide) is administered according to strict dosage and timing guidelines. The medicine is available for patient use in several official forms, including tablets and oral solution for at-home use, and an injectable solution for parenteral administration via the intravenous (IV) or intramuscular (IM) route, often utilized in acute care settings.


Official Dosing and Administration Timing

The standard single adult dose is typically 10 mg. For oral administration, the dose is typically taken up to three or four times daily, and it is a key instruction that the medicine be taken 30 minutes before each meal and at bedtime to align its effects with the digestive cycle. Regardless of the route of administration, a mandatory minimum interval of 6 hours must be maintained between consecutive doses.

Administration Detail Official Guideline
Standard Single Dose 10 mg
Maximum Duration (Acute) 5 days
IV Administration Rate Must be given slowly over at least 3 minutes

Duration and Population-Specific Use

Treatment duration is strictly limited. For acute antiemetic use, the duration generally does not exceed 5 consecutive days. For long-term conditions like symptomatic diabetic gastroparesis, oral therapy is typically limited to a period of 2 to 8 weeks. Dose adjustments are required for certain patient groups: the total daily dose should be reduced by 50% in patients with severe renal impairment (creatinine clearance less than 60 mL/min) or severe hepatic impairment.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of studies for Metoclopramida Labesfal

Evidence for use in Acute Nausea and Vomiting

Research primarily involves systematic reviews and Randomized Controlled Trials (RCTs) examining the medicine's role in preventing sickness after surgery (PONV) and in acute symptoms related to migraine headaches or chemotherapy (CINV). Studies monitored physical discomfort and examined the incidence of vomiting and the need for rescue antiemetic medications. Findings describe patterns observed in these time-limited trials, with some comparative studies showing mixed results. Evidence quality varies, and research for nausea alone is often a secondary outcome, which suggests certainty may be lower.

Evidence for use in Managing Symptoms of Sluggish Stomach Emptying

Research has explored the use of the medicine for diabetic gastroparesis through Randomized, Double-Blind, Placebo-Controlled Trials. Studies monitored both patient-reported outcomes (nausea, fullness) and objective measures of stomach emptying time. Research explored how reliably the change in reported symptoms correlated with the objective physiological change, and findings were mixed. Evidence is limited for individuals whose symptoms do not respond well to initial study periods.

Long-term studies and follow-up duration

The majority of research was evaluated in settings relevant to short-term or episodic symptom patterns, with most antiemetic trials lasting no more than five days. Due to regulatory considerations concerning prolonged use, regulators have placed restrictions on the maximum duration of use. Consequently, long-term effects remain not fully established, and there is limited information for long-term outcomes regarding the durability of any observed response.

Evidence in special populations and research gaps

Research has explored its use in specific patient groups, including children (age ge 1 year) and individuals with impaired kidney or liver function. Studies observed that children may have a different reporting profile for certain movement-related issues compared to adults. Studies suggest that the amount administered may require modification for patients with moderate to severe kidney or liver impairment. Data gaps persist, and comparative evidence remains lacking for many specific patient subgroups. Research provides context but not individual predictions; findings describe group patterns, not personal outcomes.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Metoclopramida Labesfal (FAQ)

Q: What is Metoclopramida Labesfal and what is its primary use?

A: Metoclopramida Labesfal is a medication that belongs to a class of drugs called prokinetic agents. It has received regulatory approval for use in certain gastrointestinal conditions, such as managing symptoms of nausea and vomiting, particularly those associated with specific medical procedures or other treatments.

Q: How does Metoclopramida Labesfal act within the body?

A: The medication is understood to function by affecting the activity of dopamine in the central nervous system and the digestive tract. This action may result in an increase in the movement of the stomach and upper intestine, helping to accelerate the emptying of the stomach content.

Q: Is this medication available for all patients experiencing digestive upset?

A: No, the use of Metoclopramida Labesfal is not appropriate for all types of digestive upset. Its use is limited to specific, approved indications and conditions. Patients should consult a healthcare professional to determine if this medication is appropriate for their specific health needs.

Q: Are there common side effects associated with the use of Metoclopramida Labesfal?

A: Clinical data indicates that, like most medications, Metoclopramida Labesfal may be associated with side effects. Common reported adverse events may include drowsiness, restlessness, fatigue, and diarrhea. These effects were noted in controlled trials.

Q: Can Metoclopramida Labesfal be used long-term?

A: Healthcare guidance generally advises that treatment with this medication should typically be limited in duration. Use beyond the prescribed period should be reviewed and monitored by a qualified healthcare provider. Prolonged use has been associated with an increased potential for certain neurological side effects.

Q: What is the most important consideration before starting Metoclopramida Labesfal?

A: Before starting this medication, it is essential to disclose a complete medical history to a healthcare professional, including any known conditions or concurrent medications. Particular attention should be paid to any history of epilepsy, gastrointestinal bleeding, or Parkinson's disease, as these conditions may influence the appropriateness of use.

Advertisements

How should Metoclopramida Labesfal be stored and disposed of?

Metoclopramida Labesfal (Metoclopramide Injection) requires strict storage conditions as defined by regulatory documents. The medicine must be stored below 30 C or 25 C and protected from light. It is explicitly required that the product not be stored in the refrigerator or freezer. Keep the ampoules or vials in the original outer carton to maintain light protection. The solution is for single use only; it must be used immediately after opening, and any remaining portion must be discarded, as the solution contains no preservative. The medicine must be kept out of the reach and sight of children. Disposal of all unused or expired product must be managed in accordance with local pharmaceutical waste requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Metoclopramida Labesfal found in:

A-Z Index: